EUVIMEDEUVIMED entdecken
Crossref

The use of oclacitinib compared to azathioprine in the management of canine pemphigus foliaceus: A retrospective analysis

Andrea Hernandez-Bures iD, Wille A Bidot iD, Craig E Griffin, Wayne S Rosenkrantz iD

Veterinary Dermatology · 2023

DOI: 10.1111/vde.13203 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Veterinary Dermatology, 2023. Verfasst von Andrea Hernandez-Bures und 3 weiteren Autor:innen. Beteiligte Einrichtung: Animal Dermatology Group Inc, Tustin, California, USA. Hauptthemen laut MEDLINE: Pemphigus, Dog Diseases. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Oclacitinib (Apoquel; Zoetis) has been reported to be beneficial for treating immune‐mediated disorders. Hypothesis/Objectives This retrospective study evaluates in which group of dogs [oclacitinib (OC) or azathioprine (AZ)] remission of pemphigus foliaceus (PF) was more effectively achieved with matched induction dosing of glucocorticoids; it further evaluates which group had a higher glucocorticoid‐sparing effect. Animals Review of 30 medical records of dogs diagnosed with PF presented to a private practice dermatological service. Materials and Methods Retrospective analysis of dogs diagnosed with PF and treated with OC or AZ in combination with glucocorticoids.

Results

There was no significant difference in the ability to induce remission between AZ and OC groups. In the AZ group, 13 of 15 dogs went into some type of remission (partial or complete), compared with 11 of 15 in the OC group. There was no significant difference between the two groups for the glucocorticoid‐sparing effect. The AZ group had an average reduction of 77.9% from the induction glucocorticoid dose, and OC group had an average reduction of 64.4%. One of 15 patients in the AZ group and three of 15 patients in the OC group had a 100% reduction of the glucocorticoid dose. Conclusions and Clinical Relevance These results indicate that OC can be considered as a treatment option for canine PF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PemphigusDog DiseasesHumansDogsAnimalsAzathioprineGlucocorticoidsRetrospective StudiesPyrimidinesSulfonamides

Stichwörter der Autor:innen

Apoquelazathioprinecanineglucocorticoidsoclacitinibpemphigus foliaceus

Substanzen

AzathioprineGlucocorticoidsoclacitinibPyrimidinesSulfonamides

Autor:innen und Institutionen

  • Animal Dermatology Group Inc, Tustin, California, USA.
  • Office of Animal Resources, Western University of Health Sciences, Pomona, California, USA.
  • Animal Dermatology Group Inc, Las Vegas, Nevada, USA.

ORCID-Profile: Andrea Hernandez-Bures, Wille A Bidot, Wayne S Rosenkrantz

Zitieren

APA

Hernandez-Bures, A., Bidot, W. A., Griffin, C. E., & Rosenkrantz, W. S. (2023). The use of oclacitinib compared to azathioprine in the management of canine pemphigus foliaceus: A retrospective analysis. Veterinary Dermatology. https://doi.org/10.1111/vde.13203

Vancouver

Hernandez-Bures A, Bidot WA, Griffin CE, Rosenkrantz WS. The use of oclacitinib compared to azathioprine in the management of canine pemphigus foliaceus: A retrospective analysis. Veterinary Dermatology. 2023. doi:10.1111/vde.13203

BibTeX
@article{HernandezBures2023,
  author = {Hernandez-Bures, Andrea and Bidot, Wille A and Griffin, Craig E and Rosenkrantz, Wayne S},
  title = {The use of oclacitinib compared to azathioprine in the management of canine pemphigus foliaceus: A retrospective analysis},
  journal = {Veterinary Dermatology},
  year = {2023},
  doi = {10.1111/vde.13203}
}
Kostenlos starten →